Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Novartis Pharmaceuticals Corporation","sponsor":"Harrow","pharmaFlowCategory":"D","amount":"$175.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to Ilevro\u00ae, Nevanac\u00ae, Vigamox\u00ae, Maxidex\u00ae, And Triesence\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"},{"orgOrder":0,"company":"Harrow","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Harrow Closes Acquisition of U.S. Rights to ILEVRO\u00ae, NEVANAC\u00ae, VIGAMOX\u00ae, MAXIDEX\u00ae, and TRIESENCE\u00ae and Will Begin Receiving Net Profit Payments for Acquired Products","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"January 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Nepafenac

    Menu

    Nepafenac

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Harrow

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products

              Details:

              Ilevro (nepafenac) is a non-steroidal anti-inflammatory drug (NSAID). It stops the body from making chemicals that cause inflammation, which helps lessen pain and swelling in the eye due to surgery.

              Lead Product(s): Nepafenac

              Therapeutic Area: Ophthalmology Product Name: Ilevro

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

              Deal Size: $130.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition January 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Novartis Pharmaceuticals Corporation

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Switzerland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to Ilevro®, Nevanac®, Vigamox®, Maxidex®, And Triesence®

              Details:

              Ilevro® (nepafenac ophthalmic suspension) is a 0.3%, a non-steroidal, anti-inflammatory eye drop indicated for pain and inflammation associated with cataract surgery.

              Lead Product(s): Nepafenac

              Therapeutic Area: Ophthalmology Product Name: Ilevro

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Harrow

              Deal Size: $175.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition December 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY